Company Description: Adge Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of best-in-class therapies for the management of obesity and metabolic syndrome. Adge Pharmaceuticals Inc. has begun evaluating elocalcitol, a.k.a. RO269228, a clinical stage small molecule originally developed by Roche, for the treatment of obesity and potentially other related indications with unmet medical needs. The discovery of novel mechanism of action provides Adge with a powerful proprietary platform for the treatment of obesity and metabolic syndrome. Adge has complemented the already existing data package with relevant preclinical data supporting its use for the treatment and prevention of obesity and metabolic syndrome and is preparing to move this asset expeditiously back to the clinic.